Concepedia

Author

Anna Schreiber

University of Colorado Anschutz Medical CampusORCID

Also Known As

A. Schreiber, Anna R Schreiber, Anna R. Schreiber, Anna Rochelle Schreiber, Anna Schreiber

57

Publications

313

Citations

10

H-Index

0

Concepts

All Affiliations

University of Colorado Anschutz Medical CampusUniversity of Colorado Cancer CenterUniversity of Colorado DenverThe University of Texas at AustinNational Cancer Centre Singapore
AS

About

Anna Schreiber is an author at University of Colorado Anschutz Medical Campus.

Anna Schreiber

×

8

Publications

182

Citations

8

H-Index

YearCitations

Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms

Aaron J. Scott, John J. Arcaroli, Stacey M. Bagby,

Molecular Cancer Therapeutics

2018

44

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

Kevin S. Quackenbush, Stacey M. Bagby, Wai Meng David Tai,

Oncotarget

2016

39

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Stephen G. Smoots, Anna Schreiber, Marilyn M. Jackson,

Breast Cancer Research

2024

23

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Justin Greene, Anna Nguyen, Stacey M. Bagby,

Oncotarget

2017

22

Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials

Anna Schreiber, Jodi Kagihara, Jennifer Weiss,

Frontiers in Oncology

2021

20

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study

Anna Schreiber, Jodi Kagihara, Megan Eguchi,

Breast Cancer Research and Treatment

2021

13

Tackling metastatic triple-negative breast cancer with sacituzumab govitecan

Anna Schreiber, Michelle Andress, Jennifer R. Diamond

Expert Review of Anticancer Therapy

2021

11

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy

Nisha Holay, Alexander Somma, Mark Duchow,

Frontiers in Immunology

2023

10

Page 1